NEW YORK – Integrated DNA Technologies and Chinese medical sequencing firm ChosenMed are jointly developing large pan-cancer gene panels as part of the Cancer Genome Atlas of China (CGAC) project, IDT said today.
Under the strategic collaboration, IDT, a unit of Danaher, will provide its next-generation sequencing enrichment products for cancer sequencing to Beijing-based ChosenMed and help to enhance the firm's R&D capabilities.
Financial details of the agreement were not disclosed.
"This strategic cooperation allows our two organizations to leverage expertise in a joint effort to address future clinical needs," IDT President Trey Martin said in a statement.
IDT said the CGAC project, which is led by a Chinese government department that provides national standards for the registration of medical devices, has identified a clinical need for a large pan-cancer panel to standardize cancer diagnoses for Chinese patients. The two companies "will work together to build and develop future standards for NGS-based cancer diagnosis and, ultimately, treatment in China," according to IDT.